[1]朱有志,郑珂,张惠灏,等.MicroRNA-155在甲状腺乳头状癌中的表达及临床意义[J].南方医科大学学报,2016,(10):1364.
点击复制

MicroRNA-155在甲状腺乳头状癌中的表达及临床意义()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2016年10期
页码:
1364
栏目:
出版日期:
2016-10-15

文章信息/Info

Title:
Expression of microRNA-155 in papillary thyroid carcinoma and its clinical significance
作者:
朱有志郑珂张惠灏陈玲吴坤琳任彩虹王宗财孔令君阮炜鸿陈祥锦
关键词:
甲状腺肿瘤甲状腺乳头状癌MicroRNA-155
Keywords:
thyroid tumor papillary thyroid carcinoma microRNA-155
摘要:
目的探讨microRNA-155(miR-155)在甲状腺乳头状癌(papillary thyroid cancer, PTC)患者中的表达情况及与临床病理 特征的相关性,miR-155指导PTC预后的可行性。方法收集86例PTC患者的癌及癌旁新鲜组织,用荧光定量PCR的方法检测 miR-155在上述组织中的表达,并结合其临床病理特点进行回顾性分析。结果69.8%(60/86)的PTC患者癌组织的miR-155表 达较癌旁正常组织上调,相对上调倍数为2.63±2.73倍;而在表达上调组中,PTC原发灶更大[(1.66±0.96)cm vs(1.19±0.52)cm, P=0.021];更容易出现甲状腺包膜外侵犯(56.7% vs 23.1%,P=0.004);淋巴结转移率更高(70% vs 46.2%,P=0.036);具有更晚的 TNM分期,Ⅲ~Ⅳ期的比例更高(20% vs 0%,P=0.014)。PTC癌组织中miR-155相对表达量(ΔCT)高低与淋巴结转移个数具备 一定的相关性(r=0.531,P=0.001)。结论PTC中miR-155的高表达具有更大肿瘤病灶,更易甲状腺包膜外侵犯,更高颈部淋巴 结转移率及更晚的TNM分期等临床病理特点,可能作为不良临床预后的判断指标之一。
Abstract:
Objective To investigate the correlation of microRNA-155 (miR-155) expression with clinicopathological features of patients with papillary thyroid carcinoma (PTC) and explore the value of miR-155 in prognostic assessment of PTC. Methods We collected 86 pairs of fresh PTC and adjacent tissues to examine the expression of miR-155 using fluorescent quantitative PCR. miR-155 expressions in the tissues were analyzed in relation to the clinicopathological features of the patients. Results Compared with the paired adjacent tissues, 69.8% (60/86) of the PTC tissues showed up-regulated miR-155 expression by 2.63± 2.73 folds. Up-regulated miR-155 expressions were associated with a larger tumor size (1.66±0.96 vs 1.19±0.52 cm, P=0.021), a higher likeliness of extrathyroid invasion (56.7% vs 23.1%, P=0.004), a higher rate of lymph node metastasis (70% vs 46.2%, P= 0.036), a more advanced TNM stage, and a higher rate of III-IV stage of the tumor (20% vs 0%, P=0.014). The expression level of miR-155 in PTC tissues was positively correlated with lymph node metastasis (r=0.531, P=0.001). Conclusion PTC patients with miR-155 over-expression tend to have a greater tumor size, a greater likeliness of extrathyroid involvement, a higher rate of cervical lymph node metastasis and a more advanced TNM stage. The high expression of miR-155 in the tumor may indicate a poor prognosis of PTC patients.

相似文献/References:

[1]孙云钢,冯会娟,刘金华,等.18F-FDG符合线路显像对甲状腺乳头状癌颈部淋巴结转移131I疗效的预测价值[J].南方医科大学学报,2011,(09):1571.
[2]杨清绪,邵春奎,冯智英,等.CK19和甲状腺过氧化物酶表达在甲状腺疾病诊断中的作用[J].南方医科大学学报,2005,(06):678.
 YANG Qing-xu,SHAO Chun-kui,FENG Zhi-ying,et al.Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases[J].Journal of Southern Medical University,2005,(10):678.
[3]刘光俊.甲状腺癌骨转移的影像学诊断[J].南方医科大学学报,2004,(08):920.
 LIU Guang-jun.Imaging diagnosis of thyroid carcinoma with bone metastasis[J].Journal of Southern Medical University,2004,(10):920.
[4]黄静,李燕萍,薛刚,等.血清VEGF-C、VEGF-D及VEGFR-3联合TSH检测在甲状腺乳头状癌诊断中的价值[J].南方医科大学学报,2014,(12):1814.
[5]王伟镇,李颖嘉.影像组学预测甲状腺乳头状癌中央区淋巴结转移[J].南方医科大学学报,2019,(09):1094.[doi:10.12122/j.issn.1673-4254.2019.09.15]

更新日期/Last Update: 1900-01-01